Fiche publication
Date publication
mars 2017
Journal
Pain
Auteurs
Membres identifiés du Cancéropôle Est :
Dr LUPORSI Elisabeth
Tous les auteurs :
Bouhassira D, Luporsi E, Krakowski I
Lien Pubmed
Résumé
This prospective national multicentre study was carried out to estimate the prevalence and incidence of chronic pain with or without neuropathic characteristics in patients with cancer in France. All consecutive outpatients (n = 1885) seen over two weeks for cancer treatment in 12 oncology units were invited to participate in the study and 1805 were included. Patients underwent a clinical examination during visit 1, and a questionnaire was completed to detect chronic pain (defined as daily pain for at least three months) and to characterise its intensity, location and neuropathic characteristics (i.e. DN4 score ≥ 4). The impact of pain on quality of life was assessed with the Brief Pain Inventory. Patients without pain at visit 1 were included in the incidence study and were seen at three and six months after visit 1.The overall prevalence of chronic pain was 28.2% [95% CI: 26.3-30.5], ranging from 22.5% to 35.4%, depending on the location of the primary tumour. Neuropathic characteristics were present in 20.9% of these patients, with a prevalence of 2.9% to 9.7%, depending on primary tumour location. Pain intensity and interference were higher in patients with neuropathic characteristics. In total, 1285 patients were included in the incidence study, 873 of whom were seen at least once, three or six months after the first visit. The incidence of chronic pain during the six-month follow-up period ranged from 13% to 28%, depending on primary tumour location, and neuropathic characteristics were found in 19.9% of patients with chronic pain.
Mots clés
Cancer Pain, diagnosis, Causality, Chronic Pain, diagnosis, Comorbidity, Female, France, epidemiology, Humans, Incidence, Longitudinal Studies, Male, Middle Aged, Neuralgia, diagnosis, Pain Measurement, statistics & numerical data, Prevalence, Reproducibility of Results, Risk Assessment, Sensitivity and Specificity
Référence
Pain. 2017 Mar;:
